Core Viewpoint - Berger Montague PC is investigating claims against CTO Realty Growth, Inc. for allegedly misleading investors regarding its financial condition and manipulating key metrics [1][2] Group 1: Legal Investigation - The investigation pertains to claims under federal securities laws against CTO Realty Growth, a real estate investment trust based in Winter Park, Florida [1] - Investors who acquired CTO securities between February 18, 2021, and June 24, 2025, have until October 7, 2025, to seek appointment as lead plaintiff [2] Group 2: Allegations and Financial Misconduct - The lawsuit alleges that CTO misled investors by overstating the profitability of properties, including Ashford Lane in Atlanta [2] - A report by Wolfpack Research accused CTO of covering a $38 million dividend shortfall by diluting shareholders, increasing the outstanding share count by 70% [3] - The report also claimed CTO used a "sham loan" to conceal issues with a collapsed tenant at Ashford Lane [3] Group 3: Market Reaction - Following the allegations, CTO's stock experienced a 5.42% decline, closing at $17.10 per share on June 25, 2025 [3]

PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of CTO Realty Growth, Inc. (NYSE: CTO) ("CTO" or the "Company") following the filing of a securities class action lawsuit on behalf of investors who purchased or otherwise acquired CTO securities between February 18, 2021 through June 24, 2025 (the "Class Period").Investor Deadline: Investors who purchased or acquired CTO securities during the Class Period may, no later th ...

Core Viewpoint - Berger Montague PC is investigating claims against Fiserv, Inc. following a class action lawsuit alleging that the company overstated its growth by not disclosing issues with its Clover payment platform [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that Fiserv and certain executives failed to disclose that Clover's revenue growth was artificially inflated due to the forced transition of merchants from the legacy Payeezy platform [3]. - Investors who acquired Fiserv securities between July 24, 2024, and July 22, 2025, can seek to be appointed as lead plaintiff representatives by the deadline of September 22, 2025 [2][5]. Group 2: Financial Impact - Fiserv's share price experienced a significant decline following disclosures on July 23, 2025, when the company lowered its 2025 organic growth projections and confirmed decelerated growth in its Merchant segment [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of ad spending from open exchanges to closed platforms, which limited its technological capabilities [5]. - It is claimed that DoubleVerify's ability to monetize its high-margin advertising optimization services was significantly hampered due to the high costs and time required for technology development for closed platforms [5]. - The lawsuit also states that DoubleVerify's competitors were better positioned to integrate AI into their offerings, negatively impacting DoubleVerify's competitive edge and profitability [5]. - Additional allegations include systematic overbilling of customers for ad impressions served to declared bots and misleading risk disclosures that characterized adverse facts as mere possibilities [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - The company reported Q3 2024 financial results on October 17, 2024, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for irregularities in financial reporting related to its acquisition of Lugano Holdings, leading to a significant drop in stock price [1][3]. Group 1: Company Overview - Compass Diversified Holdings is a private equity firm headquartered in Westport, Connecticut [2]. - In 2021, Compass acquired a majority interest in Lugano Holdings, Inc., a high-end jewelry designer, for an enterprise value of $256 million [2]. Group 2: Legal Developments - The class action lawsuit pertains to investors who purchased Compass securities between May 1, 2024, and May 7, 2025 [1]. - Investors have until July 8, 2025, to seek appointment as lead plaintiff in the class action [2]. - On May 7, 2025, Compass disclosed irregularities in Lugano's financing, accounting, and inventory practices, necessitating a restatement of previously issued financial statements for 2024 [3]. Group 3: Market Impact - Following the announcement of the financial irregularities, Compass' stock price fell by $10.70 per share, a decline of over 62%, closing at $6.55 on May 8, 2025 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bitfarms Ltd. securities between March 21, 2023, and December 9, 2024, of the July 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][4]. Group 1: Class Action Details - Investors who purchased Bitfarms securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 8, 2025 [2][5]. - The lawsuit alleges that Bitfarms made false and misleading statements regarding its financial reporting and internal controls, leading to potential misstatements in financial statements [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3].

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Elevance common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of misleading statements and failure to disclose important information regarding competition and revenue guidance [3][5]. Group 1: Allegations Against Treace Medical - The complaint alleges that Treace Medical and its executives violated federal securities laws by making false and misleading statements [5]. - Key issues include the impact of competition on the demand for Treace's primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [5]. - The company had to accelerate plans for an alternative product to osteotomy due to competitive pressures [5]. Group 2: Revenue Guidance and Stock Impact - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from $220 million-$225 million to $201 million-$211 million [6]. - Following this announcement, the company's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [7]. Group 3: Legal Proceedings and Class Action - Investors who suffered losses are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][9]. - There is a June 10, 2025 deadline for investors to seek the role of lead plaintiff in the federal securities class action against Treace Medical [3].

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Avis Budget securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...